You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 61 - 70 of 6435 results
  1. Hybrid ELISA: Simple and specific one-tier assay for Lyme disease

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Abstract Lyme disease, caused by infection with the spirochete Borrelia burgdorferi or closely related species, is the most common vector-borne disease in the United States, accounting for nearly 500,000 infections per year according to recent public health estimates. It is also one of the few infectious diseases that requires a two-step laboratory testing protocol, comprising a screening assay, t ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Theranostic for gastric cancer

    SBC: COLLAGEN MEDICAL LLC            Topic: 102

    Project Summary The overarching objective of this application is to develop an image-guided therapy paradigm for improving the management of gastric cancer (GCa) by targeting fibrin in the tumor microenvironment. GCa is the fifth most common cancer and the third leading cause of cancer-related death worldwide. Despite progress in management of advanced GCa, the prognosis remains poor with a median ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Virtual Reality Train the Trainer (VRT3)

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: 500

    Project Summary/AbstractCharles River Analytics proposes to explore the feasibility of a Virtual Reality Train the Trainer (VRT3) program that addresses the critical barriers to appropriately using VR training through a Phase I effort focused on developing training and real-time support for instructors. VRT3 is significant because poorly implemented and delivered VR training can have deleterious t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Optimized Ratiometric Voltage-Sensitive Dyes for Cardiac Research, Safety Pharmacology

    SBC: POTENTIOMETRIC PROBES LLC            Topic: 400

    Project Summary/Abstract Potentiometric Probes The overall goal of this Phase II SBIR project is to commercialize tools, invented by the founders of Potentiometric Probe, LLC, for high-fidelity optical recording of electrical activity in cardiac cells, tissues, and whole hearts. Potentiometric Probes develops organic voltage-sensitive dyes (VSDs) that convert the changes in voltage across cell mem ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists

    SBC: BESSOR PHARMA, LLC            Topic: NIAID

    Abstract The SARS-CoV-2 host response is associated with wide-ranging immuno-inflammatory derangements and tissue injury. We are developing an innovative therapeutic, BP-1002, to both blunt inflammatory cytokines and protect tissues. BP-1002 has the potential to prevent organ injury and deaths from COVID-19, regardless of viral variants. BP-1002, is a renalase (RNLS) agonist - a recently discovere ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Strain-Programmed Bioadhesive Patch for Enhanced Diabetic Wound Healing

    SBC: SANAHEAL INC            Topic: 200

    ABSTRACT The objective of this proposal is to optimize and validate the strain-programmed bioadhesive patch in compliance with FDA regulatory guidance for the FDA IDE approval in advance of the future pivotal clinical trial and ultimate regulatory clearance and commercialization. In light of the huge and rapidly growing clinical and economic costs of chronic diabetic wounds and associated complica ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Time-lapse Flow Cytometry for Kinetic Profiling of T-Cell Function

    SBC: LASE INNOVATION INC            Topic: 102

    Abstract Despite progress in immunotherapies, there are significant challenges to overcome to make them more broadly applicable to different cancers and more effective for patients. However, current efforts to improve adoptive cell therapies and immune checkpoint blockade as well as cancer vaccines are hampered by the lack of a method to characterize the functional and phenotypical changes of diff ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an endometrial ablation drug-device combination to treat heavy menstrual bleeding

    SBC: GYNION, LLC            Topic: NICHD

    PROJECT SUMMARY Over 10 million women in the US and 100 million women globally suffer from Heavy Menstrual Bleeding (HMB). Oral medications lack effectiveness and, like hormonal IUDs (intrauterine devices), have significant side effects. Currently available endometrial ablation options, which is another therapeutic alternative, are complex and require advanced anesthesia, which significantly limit ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid response to pandemic influenza via multi-antigen RNA-based vaccine

    SBC: TIBA BIOTECH LLC            Topic: NIAID

    Project Abstract Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemic-potential viruses has been demonstrated by the devastating effects of COVID-19 on human health and the economy. Development of H7 Influenza vaccines has lagged, as pandemic ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Biomarker-Based Test of Cure for Chagas Disease

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Project Summary Chagas disease, caused by infection with Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an insect vector, but can also be acquired through blood transfusion, organ transplant, or congenitally. Following a brief acute phase, the parasite persist ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government